Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 11 Issue 1, March 2017

Volume 11 Issue 1

In this issue...

• Mapping collaborations in the microbiome field

• Cancer vaccine development reignited by neoantigens

• Dermatology market on brink of growth spurt

Cover image: 3D illustration of cancer cells. vitanowski, Thinkstock.

Mapping collaborations in the microbiome field

    Feature

  • News Feature |

    Partnering activity in the microbiome space exploded in 2016, and with the first inroads into clinical development well under way, 2017 is shaping up as a pivotal year for the microbiome’s therapeutic and market potential to blossom.

    • Gaspar Taroncher-Oldenburg
  • Profiles

  • Advertisement Feature |

    By leveraging an innovative discovery platform, Curileum Discovery is developing an approach based on stem cell drugs that has the potential to cure a wide range of gastrointestinal disorders.

    • Curileum Discovery
  • Advertisement Feature |

    Temple Therapeutics BV’s first-in-class phase-3-ready drug candidate for postoperative fibrosis is ready for partnering for an untapped $5 billion market.

    • Temple Therapeutics BV

Cancer vaccine development reignited by neoantigens

    Feature

  • Profiles

  • Advertisement Feature |

    A Dallas-based biotech company is leading a wave of innovation in cancer treatment that is being tailored to the cancer patients who are most likely to respond.

    • Lantern Pharma
  • Advertisement Feature |

    Tumor cells use various strategies to avoid immune reactions. Most efforts by researchers to circumvent these tactics have focused on monoclonal antibodies (mAbs) that target inhibitory checkpoints to reactivate the immune response against tumor cells. The rapidly growing field of immuno-oncology has seen the approval of several promising drugs of this kind.

    • TheraMAB LLC
  • Advertisement Feature |

    Icell Kealex Therapeutics is developing oncolytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. The company is entering phase 1 trials for solid tumors with its lead product and is looking to partner with companies interested in clinical codevelopment of its wide-ranging therapeutic pipeline.

    • Icell Kealex Therapeutics
  • Advertisement Feature |

    Aposense is exploring an overlooked powerful electric field present at the depth of every biological membrane, in order to energize a pipeline of therapeutic opportunities.

    • Aposense

Dermatology market on brink of growth spurt

    Feature

  • News Feature |

    Exploration by biopharma companies of new biological pathways underlying skin disorders is leading to the entry of potential blockbusters into the dermatology market, and fueling high-value deals.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    NanoViricides, Inc. has developed unique micelles termed nanoviricides that can bind and inactivate viruses, including those that cause shingles and genital ulcers.

    • NanoViricides, Inc.

Search

Quick links